keyword
https://read.qxmd.com/read/38536619/acceptability-and-feasibility-of-the-plasma-separation-card-for-an-integrated-model-of-care-for-hbv-and-hcv-screening-among-people-attending-hiv-clinics-in-cameroon-and-uganda
#1
JOURNAL ARTICLE
Camila A Picchio, Aina Nicolàs, Ironne Valdèse Ayemfouo Fofou, Viola Kasone, Magellan Guewo-Fokeng, Claude T Tagny, Teddy Nanyonjo, Hellen Nansumba, Yves Nacel Kouongni, Rita Gaëlle Epse Sezawo Kamdjeu, Emmanuel Seremba, Charles Kouanfack, Isaac Ssewanyana, Richard Njouom, Ariadna Rando Segura, Francisco Rodríguez-Frías, Jean Claude Mbanya, Ponsiano Ocama, Jeffrey V Lazarus
BACKGROUND: Sub-Saharan African countries have a high burden of viral hepatitis and poor access to screening and care. The aim of this study was to evaluate the feasibility and acceptability of using the plasma separation card (PSC) for viral hepatitis B and C screening among people living with HIV (PLHIV) in Cameroon and Uganda. METHODS: This is a cross-sectional study carried out between 05/2021 and 03/2023 including 192 PLHIV in Cameroon (n = 104) and Uganda (n = 88)...
March 27, 2024: Journal of Epidemiology and Global Health
https://read.qxmd.com/read/38535599/alterations-in-n-glycosylation-of-hcv-e2-protein-in-children-patients-with-ifn-rbv-therapy-failure
#2
JOURNAL ARTICLE
Karolina Zimmer, Alicja M Chmielewska, Paulina Jackowiak, Marek Figlerowicz, Krystyna Bienkowska-Szewczyk
The glycosylation of viral envelope proteins plays an important role in virus biology and the immune response of the host to infection. Hepatitis C virus (HCV) envelope proteins E1 and E2, key players in virus entry and spread, are highly N-glycosylated and possess 4 (5 in certain genotypes) to 11 conserved glycosylation sites, respectively. Many published results based on recombinant proteins indicate that the glycan shield can mask the epitopes targeted by neutralizing antibodies. Glycan shifting within the conserved linear E2 region (412-423) could be one of the escape strategies used by HCV...
March 15, 2024: Pathogens
https://read.qxmd.com/read/38535558/hepatitis-c-epidemiology-insights-from-a-comprehensive-cohort-study-in-asst-melegnano-and-martesana-lombardia-region-northern-italy
#3
JOURNAL ARTICLE
Michele Nardone, Dario Di Stasio, Alberta Lucchese, Daniele Gentili, Giulia Cattabianchi, Carlo Signorelli, Pierangelo Sarchi, Giovanna Pulcrano, Valentino Lembo, Paola Maria Pirola, Dorina Lauritano, Francesco Carinci
Hepatitis C virus (HCV) infection is a significant public health problem affecting 58 million people worldwide, including 3.9 million in Europe. Many of these infections go undiagnosed because chronic infection is often asymptomatic. This observational cohort study presents a detailed examination of hepatitis C virus epidemiology in Lombardia (Italy) and was conducted within the ASST "Melegnano e della Martesana". The study involved comprehensive HCV screening of 3290 patients accessing the collection points and/or hospitalized in the facilities of the ASST from 20 May 2022 to 13 April 2023...
February 28, 2024: Pathogens
https://read.qxmd.com/read/38534991/evaluation-of-two-assay-serological-testing-strategies-for-anti-hcv-screening-in-italian-populations-a-dual-screening-approach
#4
JOURNAL ARTICLE
Elena Zocca, Silva Seraceni, Teresa Cafaro, Tamara Emanuela Cervone, Laura Cardarelli, Massimiliano Valisi, Isabella Polidori, Massimo Pieri, Flaminia Tomassetti, Francesco Broccolo
(1) Background: Hepatitis C virus (HCV) screening mostly uses a one-assay anti-HCV testing approach, which has a higher probability of false-positive results in populations with low HCV prevalence. (2) Methods: In this investigation, 17,926 participants were screened for HCV, and the reactives were tested using a two-assay anti-HCV approach: Elecsys ElectroChemiLuminescence (ECL) and a ChemiLuminescence ImmunoAssay (CLIA), respectively. A recombinant immunoblot assay (RIBA) was performed to confirm anti-HCV positivity...
March 7, 2024: Diagnostics
https://read.qxmd.com/read/38534007/high-hepatitis-c-cure-rates-among-patients-with-alcohol-use-at-a-safety-net-hepatitis-c-clinic
#5
JOURNAL ARTICLE
Erica Heiman, Meghan Alexander, Rebecca Zhang, Ziduo Zheng, Lesley S Miller
OBJECTIVES: We set out to examine several aspects of the relationship between alcohol use and hepatitis C virus (HCV) among a cohort of patients treated at an HCV clinic within a safety net hospital. We examined (1) the prevalence of alcohol use among patients treated for HCV, (2) the likelihood of being started on treatment among patients who reported drinking alcohol compared with those who did not, and (3) the associations between alcohol use and HCV cure. METHODS: We performed a retrospective chart abstraction study using data from the Grady Liver Clinic, a specialty HCV clinic colocated in Grady Memorial Hospital's primary care clinic and run by general internists...
March 27, 2024: Journal of Addiction Medicine
https://read.qxmd.com/read/38532435/liver-stiffness-and-associated-risk-factors-among-people-with-a-history-of-injecting-drugs-a-prospective-cohort-study
#6
JOURNAL ARTICLE
Karl Trygve Druckrey-Fiskaaen, Jørn Henrik Vold, Tesfaye Madebo, Håvard Midgard, Olav Dalgard, Rafael Alexander Leiva, Lars T Fadnes
BACKGROUND: Persons with opioid use disorders (OUD) and persons with substance use disorders (SUD) who inject substances have a reduced life expectancy of up to 25 years compared with the general population. Chronic liver diseases are a substantial cause of this. Screening strategies based on liver stiffness measurements (LSM) may facilitate early detection, timely intervention, and treatment of liver disease. This study aims to investigate the extent of chronic liver disease measured with transient elastography and the association between LSM and various risk factors, including substance use patterns, hepatitis C virus (HCV) infection, alcohol use, body mass index, age, type 2 diabetes mellitus, and high-density lipoprotein (HDL) cholesterol among people with OUD or with SUD who inject substances...
March 26, 2024: Substance Abuse Treatment, Prevention, and Policy
https://read.qxmd.com/read/38531730/hepatitis-c-virus-infection-and-co-infection-with-hiv-among-persons-who-inject-drugs-in-10-u-s-cities-national-hiv-behavioral-surveillance-2018
#7
JOURNAL ARTICLE
Johanna Chapin-Bardales, Alice Asher, Dita Broz, Eyasu Teshale, Tonya Mixson-Hayden, Amanda Poe, Senad Handanagic, Carlos Blanco, Cyprian Wejnert
BACKGROUND: Characterizing acute and chronic hepatitis C virus (HCV) infection and HIV/HCV co-infection among persons who inject drugs (PWID) can inform elimination efforts. METHODS: During 2018 National HIV Behavioral Surveillance in 10 U.S. metropolitan statistical areas (MSAs), PWID were recruited using respondent-driven sampling and offered a survey, HIV testing, and HCV antibody and RNA testing. We examined prevalence and associated characteristics of HCV infection and HIV/HCV co-infection...
March 25, 2024: International Journal on Drug Policy
https://read.qxmd.com/read/38528584/potential-use-of-proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibition-and-prevention-method-in-viral-infection
#8
REVIEW
Khursheed Muzammil, Mohammad Hosseini Hooshiar, Shirin Varmazyar, Thabit Moath Omar, Manal Morad Karim, Sadeq Aadi, Shaylan Kalavi, Saman Yasamineh
Cellular lipid membranes serve as the primary barrier preventing viral infection of the host cell and provide viruses with a critical initial point of contact. Occasionally, viruses can utilize lipids as viral receptors. Viruses depend significantly on lipid rafts for infection at virtually every stage of their life cycle. The pivotal role that proprotein convertase subtilisin/kexin Type 9 (PCSK9) plays in cholesterol homeostasis and atherosclerosis, primarily by post-transcriptionally regulating hepatic low-density lipoprotein receptor (LDLR) and promoting its lysosomal degradation, has garnered increasing interest...
March 25, 2024: Microbial Cell Factories
https://read.qxmd.com/read/38528570/project-chariot-study-protocol-for-a-hybrid-type-1-effectiveness-implementation-study-of-comprehensive-tele-harm-reduction-for-engagement-of-people-who-inject-drugs-in-hiv-prevention-services
#9
JOURNAL ARTICLE
Tyler S Bartholomew, Marina Plesons, David P Serota, Elizabeth Alonso, Lisa R Metsch, Daniel J Feaster, Jessica Ucha, Edward Suarez, David W Forrest, Teresa A Chueng, Katrina Ciraldo, Jimmie Brooks, Justin D Smith, Joshua A Barocas, Hansel E Tookes
BACKGROUND: People who inject drugs (PWID) remain a high priority population under the federal Ending the HIV Epidemic initiative with 11% of new HIV infections attributable to injection drug use. There is a critical need for innovative, efficacious, scalable, and community-driven models of healthcare in non-stigmatizing settings for PWID. We seek to test a Comprehensive-TeleHarm Reduction (C-THR) intervention for HIV prevention services delivered via a syringe services program (SSP)...
March 25, 2024: Addiction Science & Clinical Practice
https://read.qxmd.com/read/38528292/global-burden-and-trends-of-acute-viral-hepatitis-among-children-and-adolescents-from-1990-to-2019-a-systematic-analysis-of-the-global-burden-of-disease-study-2019
#10
JOURNAL ARTICLE
Wanglong Xiao, Jingwei Zhao, Yiwen Chen, Xingzhu Liu, Chang Xu, Jiaxu Zhang, Yongbing Qian, Qiang Xia
BACKGROUND: Children and adolescents are at high risk for acute viral hepatitis (AVH), but epidemiological research focusing on them has been overshadowed by adult chronic B and C. We provide global, regional, and national estimates of the AVH burden and their trends on people under 20 years from 1990 to 2019. METHODS: AVH data from Global Burden of Disease Study (GBD) 2019 was used. Incidence and disability-adjusted life years (DALYs) were calculated, analyzing trends with estimated annual percentage change (EAPC) and Joinpoint regression...
March 26, 2024: Hepatology International
https://read.qxmd.com/read/38528198/clinical-features-of-patients-with-hepatocellular-carcinoma-treated-with-radiofrequency-ablation-therapy-developing-a-simple-score-to-determine-the-need-for-immune-adjuvant-therapy
#11
JOURNAL ARTICLE
Fujimasa Tada, Atsushi Hiraoka, Kosuke Nakatani, Kana Matsuoka, Mai Fukumoto, Takuya Matsuda, Emi Yanagihara, Hironobu Saneto, Taisei Murakami, Kei Onishi, Hirofumi Izumoto, Shogo Kitahata, Kozue Kanemitsu-Okada, Tomoe Kawamura, Taira Kuroda, Jun Hanaoka, Jota Watanabe, Hiromi Ohtani, Osamu Yoshida, Masashi Hirooka, Hideki Miyata, Eiji Tsubouchi, Masanori Abe, Bunzo Matsuura, Tomoyuki Ninomiya, Yoichi Hiasa
BACKGROUND/AIM: Unresectable recurrence after curative treatments for hepatocellular carcinoma (HCC) is a life-limited event. Although the IMbrave050 trial (IM050) showed a favorable reduction in recurrence with adjuvant immune-combination chemotherapy, inclusion criteria of the radiofrequency ablation (RFA) group were lower risk than that of the resection group. This study aimed to elucidate the clinical features of patients treated with RFA, which really need adjuvant-chemotherapy. METHODS: From 2000 to 2022, 528 patients with Child-Pugh A and HCC within the Milan criteria (MC), who met the IM050 criteria for RFA and undergone resection or RFA, were enrolled (71 years, HCV:HBV:HBV/HCV:alcohol:others = 337:44:5:53:89, multi-tumor = 138, RFA:resection = 309:219)...
March 26, 2024: Clinical Journal of Gastroenterology
https://read.qxmd.com/read/38526638/continuing-low-awareness-and-use-of-pre-exposure-prophylaxis-prep-for-hiv-among-people-who-inject-drugs-pwid-san-francisco-2022
#12
JOURNAL ARTICLE
Bow Suprasert, Moranda Tate, Danyion Reagan, Raul Ruiz, Katherine Gao, Katherine McNaughton, Kassandra Miller, Alexander Marr, Kelly D Taylor, Erin C Wilson, Willi McFarland
Clinical trials provide evidence that pre-exposure prophylaxis (PrEP) prevents HIV acquisition including through sharing of injection equipment among people who inject drugs (PWID). However, uptake among many populations at risk for HIV has been slow, particularly among PWID. We examined data from the National HIV Behavioral Surveillance (NHBS) from San Francisco in 2022 to measure PrEP uptake and identify factors associated with PrEP awareness among PWID. Of 479 PWID with HIV-negative or unknown HIV status, 54...
March 25, 2024: AIDS and Behavior
https://read.qxmd.com/read/38524607/viruses-and-thrombocytopenia
#13
REVIEW
Reyhaneh Rasizadeh, Fatemeh Ebrahimi, Atefeh Zamani Kermanshahi, Amin Daei Sorkhabi, Aila Sarkesh, Javid Sadri Nahand, Hossein Bannazadeh Baghi
Thrombocytopenia, characterized by a decrease in platelet count, is a multifaceted clinical manifestation that can arise from various underlying causes. This review delves into the intriguing nexus between viruses and thrombocytopenia, shedding light on intricate pathophysiological mechanisms and highlighting the pivotal role of platelets in viral infections. The review further navigates the landscape of thrombocytopenia in relation to specific viruses, and sheds light on the diverse mechanisms through which hepatitis C virus (HCV), measles virus, parvovirus B19, and other viral agents contribute to platelet depletion...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38523735/risk-factors-for-development-of-cirrhosis-in-chronic-viral-hepatitis-b-patients-who-had-persistent-viral-suppression-with-antiviral-therapy
#14
JOURNAL ARTICLE
Soe T Maung, Pakanat Decharatanachart, Sombat Treeprasertsuk, Roongruedee Chaiteerakij
BACKGROUND AND AIMS: Chronic viral hepatitis B (CHB)-infected patients occasionally develop cirrhosis despite having persistent viral suppression with antiviral therapy. We aimed to identify risk factors for developing cirrhosis in hepatitis B virus (HBV)-suppressed patients. METHODS: We conducted a case-control study involving 120 noncirrhotic CHB-infected patients achieving viral suppression with antiviral treatment, with 40 cases developing cirrhosis and 80 age-, sex-, and Fibrosis-4 (FIB-4)-matched controls...
2024: Journal of Clinical and Experimental Hepatology
https://read.qxmd.com/read/38521947/hiv-and-hepatitis-b-c-co-infection-and-correlates-of-hiv-infection-among-men-who-have-sex-with-men-in-rwanda-2021-a-respondent-driven-sampling-cross-sectional-study
#15
JOURNAL ARTICLE
Eric Remera, Elysee Tuyishime, Catherine Kayitesi, Samuel S Malamba, Beata Sangwayire, Justine Umutesi, Horacio Ruisenor-Escudero, Tom Oluoch
BACKGROUND: Men who have sex with men (MSM) are a key population group disproportionately affected by HIV and other sexually transmitted infections (STIs) worldwide. In Rwanda, the HIV epidemic remains a significant public health concern, and understanding the burden of HIV and hepatitis B and C coinfections among MSM is crucial for designing effective prevention and control strategies. This study aims to determine the prevalence of HIV, hepatitis B, and hepatitis C infections among MSM in Rwanda and identify correlates associated with HIV infection within this population...
March 23, 2024: BMC Infectious Diseases
https://read.qxmd.com/read/38521170/post-treatment-lsm-rather-than-change-during-treatment-predicts-decompensation-in-patients-with-cacld-after-hcv-cure
#16
JOURNAL ARTICLE
Georg Semmler, Sonia Alonso López, Monica Pons, Sabela Lens, Elton Dajti, Marie Griemsmann, Alberto Zanetto, Lukas Burghart, Stefanie Hametner-Schreil, Lukas Hartl, Marisa Manzano, Sergio Rodriguez-Tajes, Paola Zanaga, Michael Schwarz, María Luisa Gutierrez, Mathias Jachs, Anna Pocurull, Benjamín Polo, Dominik Ecker, Beatriz Mateos, Sonia Izquierdo, Yolanda Real, Adriana Ahumada, David Josef Maria Bauer, Jim Benjamin Mauz, Michelle Casanova-Cabral, Michael Gschwantler, Francesco Paolo Russo, Francesco Azzaroli, Benjamin Maasoumy, Thomas Reiberger, Xavier Forns, Joan Genesca, Rafael Bañares, Mattias Mandorfer
BACKGROUND & AIMS: Baveno VII has defined a clinically significant (i.e., prognostically meaningful) liver stiffness measurement (LSM)-decrease in cACLD by ≥20% associated with a final LSM<20 kPa, or any decrease to <10 kPa. However, these rules have not yet been validated against direct clinical endpoints. METHODS: We retrospectively analysed cACLD patients (LSM≥10 kPa) with paired liver stiffness measurement (LSM) before (BL) and after (FU) HCV-cure by interferon-free therapies from 15 European centers...
March 21, 2024: Journal of Hepatology
https://read.qxmd.com/read/38520313/impact-of-il-10-gene-promoter-polymorphisms-on-treatment-response-in-hcv-patients-a-systematic-review-a-meta-analysis-and-a-meta-regression
#17
JOURNAL ARTICLE
Tarak Dhaouadi, Awatef Riahi, Taïeb Ben Abdallah, Yousr Gorgi, Imen Sfar
The impact of interleukin-10 (IL-10) gene promoter polymorphisms (SNPs) on treatment response in HCV patients was dissimilarly estimated. Hence, the aim of this meta-analysis was to robustly assess the effect of IL-10 SNPs on treatment response in HCV patients. An electronic literature search was carried out through PubMed, EMBASE, Web of science, and Scopus databases. Studies assessing the association between IL-10 polymorphisms and treatment response in HCV patients were included. Studies were excluded if genotype frequencies are not consistent with the Hardy-Weinberg Equilibrium (HWE) or in case of including patients with hepatitis B virus coinfection...
2024: International Journal of Immunopathology and Pharmacology
https://read.qxmd.com/read/38518779/convergent-evolution-and-targeting-of-diverse-e2-epitopes-by-human-broadly-neutralizing-antibodies-are-associated-with-hcv-clearance
#18
JOURNAL ARTICLE
Clinton O Ogega, Nicole E Skinner, Marta V Schoenle, Xander E Wilcox, Nicole Frumento, Desiree A Wright, Harry T Paul, Ariadne Sinnis-Bourozikas, Kaitlyn E Clark, Alexis Figueroa, Pamela J Bjorkman, Stuart C Ray, Andrew I Flyak, Justin R Bailey
The early appearance of broadly neutralizing antibodies (bNAbs) in serum is associated with spontaneous hepatitis C virus (HCV) clearance, but to date, the majority of bNAbs have been isolated from chronically infected donors. Most of these bNAbs use the VH 1-69 gene segment and target the envelope glycoprotein E2 front layer. Here, we performed longitudinal B cell receptor (BCR) repertoire analysis on an elite neutralizer who spontaneously cleared multiple HCV infections. We isolated 10,680 E2-reactive B cells, performed BCR sequencing, characterized monoclonal B cell cultures, and isolated bNAbs...
March 15, 2024: Immunity
https://read.qxmd.com/read/38518542/elucidating-the-association-between-direct-acting-antivirals-and-parkinson-s-disease-in-patients-with-hepatitis-c-virus-infection
#19
JOURNAL ARTICLE
Pilar Hernandez-Con, Raj Desai, David Nelson, Haesuk Park
BACKGROUND: Some epidemiological studies have found an increased association between Parkinson's disease (PD) and chronic hepatitis C virus (HCV) infection. Although a few studies have also found a decreased risk of PD with interferon-α therapy, the effect of direct-acting antivirals (DAAs) on Parkinson's disease remains unclear. The current study seeks to assess and elucidate the association between DAAs and PD in patients newly diagnosed with chronic HCV infection. METHODS: We conducted a retrospective cohort study of patients ≥18 years diagnosed with HCV using MarketScan Commercial and Medicare Supplemental database (2012-2019)...
March 19, 2024: Parkinsonism & related Disorders
https://read.qxmd.com/read/38516962/an-international-review-of-the-characteristics-of-viral-nucleic-acid-amplification-testing-nat-reveals-a-trend-towards-the-use-of-smaller-pool-sizes-and-individual-donation-nat
#20
JOURNAL ARTICLE
Helen M Faddy, Carla Osiowy, Brian Custer, Michael Busch, Susan L Stramer, Melinda M Dean, Jessika Acutt, Elvina Viennet, Thijs van de Laar, Wai-Chiu Tsoi, Claire Styles, Phil Kiely, Angelo Margaritis, So-Yong Kwon, Yan Qiu, Xuelian Deng, Antoine Lewin, Signe Winther Jørgensen, Christian Erikstrup, David Juhl, Silvia Sauleda, Bernardo Armando Camacho Rodriguez, Lisbeth Jennifer Catherine Soto Coral, Paula Andrea Gaviria García, Sineenart Oota, Sheila F O'Brien, Silvano Wendel, Emma Castro, Laura Navarro Pérez, Heli Harvala, Katy Davison, Claire Reynolds, Lisa Jarvis, Piotr Grabarczyk, Aneta Kopacz, Magdalena Łętowska, Niamh O'Flaherty, Fiona Young, Padraig Williams, Lisa Burke, Sze Sze Chua, An Muylaert, Isabel Page, Ann Jones, Christoph Niederhauser, Marion Vermeulen, Syria Laperche, Pierre Gallian, Masahiro Satake, Marcelo Addas-Carvalho, Sebastián Blanco, Sandra V Gallego, Axel Seltsam, Marijke Weber-Schehl, Arwa Z Al-Riyami, Khuloud Al Maamari, Fatma Ba Alawi, Hem Chandra Pandey, Rochele Azevedo França, Richard Charlewood
BACKGROUND AND OBJECTIVES: Nucleic acid-amplification testing (NAT) is used for screening blood donations/donors for blood-borne viruses. We reviewed global viral NAT characteristics and NAT-yield confirmatory testing used by blood operators. MATERIALS AND METHODS: NAT characteristics and NAT-yield confirmatory testing used during 2019 was surveyed internationally by the International Society of Blood Transfusion Working Party Transfusion-Transmitted Infectious Diseases...
March 22, 2024: Vox Sanguinis
keyword
keyword
235
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.